BioAtla to Showcase Phase 1 Evalstotug Clinical Trial Outcomes Highlighting Clinical Benefits at the 2024 ASCO Annual Conference.

Sensei Biotherapeutics, Inc. has announced promising clinical results from the dose-escalation segment of its Phase 1/2 study on SNS-101.

Coherus BioSciences, Inc. presented results from the CHS-114 monotherapy dose escalation part of its Phase 1 trial at the ASCO Annual Meeting.

Cure Genetics Revealed Positive Safety and Effectiveness Data for CAR-NKT Treatment CGC729 in RCC at ASGCT 2024.

Abdera Therapeutics Inc. has revealed that the U.S. Food and Drug Administration has approved their Investigational New Drug application for ABD-147.

Aulos Bioscience revealed preliminary outcomes from its Phase 1/2 study of AU-007.

May 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Celltrion gains European Commission approval for Omlyclo® (CT-P39), the first omalizumab biosimilar sanctioned in Europe.

Recent advancements in Alzheimer's treatment are promising, with Biogen and Eisai's Leqembi receiving full approval in July, and EliLilly's donanemab potentially following suit soon.

Phase I clinical trial results for Amgen’s experimental weight-loss drug, MariTide, indicate it may provide longer-lasting effects compared to existing glucagon-like peptide-1 (GLP-1) treatments such as Novo Nordisk’s Wegovy and EliLilly’s Zepbound.

Vividion Therapeutics, a subsidiary of Bayer AG, has commenced a Phase I clinical trial for VVD-130850, an oral STAT3 inhibitor intended to treat advanced solid and hematologic tumors.

Thermosome has received approval from the Data Safety Monitoring Board (DSMB) to continue with the planned dosage increase in its Phase I clinical trial for THE001.